Forte Biosciences, Inc.
$20.31+1.20%(+$0.24)
TickerSpark Score
43/100
30
Valuation
20
Profitability
60
Growth
76
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FBRX research report →
52-Week Range46% of range
Low $7.00
Current $20.31
High $35.80
Companywww.fortebiorx.com
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.
- CEO
- Paul A. Wagner
- IPO
- 2017
- Employees
- 14
- HQ
- Dallas, TX, US
Price Chart
+166.89% · this period
Valuation
- Market Cap
- $282.02M
- P/E
- -47.76
- P/S
- 0.00
- P/B
- 86.05
- EV/EBITDA
- -2.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -106.16%
- ROIC
- -176.64%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-69,375,000 · -95.54%
- EPS
- $-4.71 · 61.30%
- Op Income
- $-70,657,000
- FCF YoY
- -65.67%
Performance & Tape
- 52W High
- $35.80
- 52W Low
- $7.00
- 50D MA
- $27.24
- 200D MA
- $21.53
- Beta
- 3.00
- Avg Volume
- 289.41K
Get TickerSpark's AI analysis on FBRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Riley Antony A | other | 375 |
| Apr 1, 26 | Riley Antony A | other | 134 |
| Apr 1, 26 | Riley Antony A | other | 375 |
| Apr 1, 26 | Wagner Paul A. | other | 1,250 |
| Apr 1, 26 | Wagner Paul A. | other | 98 |
| Apr 1, 26 | Wagner Paul A. | other | 1,250 |
| Jan 12, 26 | Riley Antony A | other | 90,000 |
| Jan 12, 26 | Riley Antony A | other | 60,000 |
| Jan 12, 26 | Wagner Paul A. | other | 270,000 |
| Jan 12, 26 | Wagner Paul A. | other | 180,000 |
Our FBRX Coverage
We haven't published any research on FBRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FBRX Report →